-
1
-
-
12644262888
-
Pharmacology of alpha-glucosidase inhibitors
-
Vasselli J, Maggio C, Scriabine A (eds.): Neva Press, Branford, Connecticut
-
Bischoff H: Pharmacology of alpha-glucosidase inhibitors. In: Vasselli J, Maggio C, Scriabine A (eds.): Drugs in development: alpha-glucosidase inhibition: potential use in diabetes. Neva Press, Branford, Connecticut, 1993: 3-13
-
(1993)
Drugs in Development: Alpha-glucosidase Inhibition: Potential Use in Diabetes
, pp. 3-13
-
-
Bischoff, H.1
-
2
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
-
(2008)
N Engl J Med
, vol.359
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
Matthews, D.R.4
Neil, H.A.5
-
3
-
-
36749059401
-
Who should benefit from the use of alpha-glucosidase inhibitors?
-
Godbout A, Chiasson JL: Who should benefit from the use of alpha-glucosidase inhibitors? Curr Diab Rep 2007; 7: 333-339
-
(2007)
Curr Diab Rep
, vol.7
, pp. 333-339
-
-
Godbout, A.1
Chiasson, J.L.2
-
4
-
-
0017668659
-
Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia
-
Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F: Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977; 64: 536-537
-
(1977)
Naturwissenschaften
, vol.64
, pp. 536-537
-
-
Puls, W.1
Keup, U.2
Krause, H.P.3
Thomas, G.4
Hoffmeister, F.5
-
5
-
-
0029147672
-
Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)
-
Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W: Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-896
-
(1995)
Scand J Gastroenterol
, vol.30
, pp. 892-896
-
-
Qualmann, C.1
Nauck, M.A.2
Holst, J.J.3
Orskov, C.4
Creutzfeldt, W.5
-
6
-
-
0028784208
-
Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve
-
Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lucker PW: Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995; 56: 493-501
-
(1995)
Digestion
, vol.56
, pp. 493-501
-
-
Goke, B.1
Fuder, H.2
Wieckhorst, G.3
Theiss, U.4
Stridde, E.5
Littke, T.6
Kleist, P.7
Arnold, R.8
Lucker, P.W.9
-
7
-
-
40149101914
-
Acarbose: Oral anti-diabetes drug with additional cardiovascular benefits
-
Hanefeld M, Schaper F: Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008; 6: 153-163
-
(2008)
Expert Rev Cardiovasc Ther
, vol.6
, pp. 153-163
-
-
Hanefeld, M.1
Schaper, F.2
-
8
-
-
0028828123
-
The effect of the timing and the administration of acarbose on postprandial hyperglycaemia
-
Rosak C, Nitzsche G, Konig P, Hofmann U: The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med 1995; 12: 979-984
-
(1995)
Diabet Med
, vol.12
, pp. 979-984
-
-
Rosak, C.1
Nitzsche, G.2
Konig, P.3
Hofmann, U.4
-
9
-
-
0028798236
-
Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM), treated with sulphonylureas
-
May C: Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM), treated with sulphonylureas. Diabetes und Stoffwechsel 1995; 4: 3-8
-
(1995)
Diabetes und Stoffwechsel
, vol.4
, pp. 3-8
-
-
May, C.1
-
10
-
-
0001891623
-
Modulation of intestinal glucose absorption: Postponement of glucose absorption by alpha-glucosidase inhibitors
-
Mogensen CE, Standl E (eds.): de Gruyter, Berlin
-
Toeller M: Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In: Mogensen CE, Standl E (eds.): Pharmacology of diabetes. de Gruyter, Berlin, 1991
-
(1991)
Pharmacology of Diabetes
-
-
Toeller, M.1
-
11
-
-
11844294865
-
Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis
-
van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163
-
(2005)
Diabetes Care
, vol.28
, pp. 154-163
-
-
Van De Laar, F.A.1
Lucassen, P.L.2
Akkermans, R.P.3
Van De Lisdonk, E.H.4
Rutten, G.E.5
Van Weel, C.6
-
12
-
-
0031847292
-
An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet
-
Asian Acarbose Study Group
-
Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R, Panelo AA, Kim DK, Embong M: An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. Diabetes Care 1998; 21: 1058-1061
-
(1998)
Diabetes Care
, vol.21
, pp. 1058-1061
-
-
Chan, J.C.1
Chan, K.W.2
Ho, L.L.3
Fuh, M.M.4
Horn, L.C.5
Sheaves, R.6
Panelo, A.A.7
Kim, D.K.8
Embong, M.9
-
13
-
-
0029133235
-
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
-
Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554
-
(1995)
N Engl J Med
, vol.333
, pp. 550-554
-
-
Stumvoll, M.1
Nurjhan, N.2
Perriello, G.3
Dailey, G.4
Gerich, J.E.5
-
14
-
-
0031762953
-
Metformin: A review of its metabolic effects
-
Cusi K, Defronzo R: Metformin: a review of its metabolic effects. Diab Rev 1998: 89-131 (Pubitemid 28554676)
-
(1998)
Diabetes Reviews
, vol.6
, Issue.2
, pp. 89-131
-
-
Cusi, K.1
Defronzo, R.A.2
-
15
-
-
0031460261
-
Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The essen-II study
-
DOI 10.1016/S0002-9343(97)00252-0, PII S0002934397002520
-
Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103: 483-490 (Pubitemid 28018650)
-
(1997)
American Journal of Medicine
, vol.103
, Issue.6
, pp. 483-490
-
-
Hoffmann, J.1
Spengler, M.2
-
16
-
-
0027947449
-
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial
-
Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935
-
(1994)
Ann Intern Med
, vol.121
, pp. 928-935
-
-
Chiasson, J.L.1
Josse, R.G.2
Hunt, J.A.3
Palmason, C.4
Rodger, N.W.5
Ross, S.A.6
Ryan, E.A.7
Tan, M.H.8
Wolever, T.M.9
-
17
-
-
0033884254
-
Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: A double-blind, placebo-controlled study
-
DOI 10.1016/S0168-8227(00)00163-7, PII S0168822700001637
-
Halimi S, Le Berre MA, Grange V: Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract 2000; 50: 49-56 (Pubitemid 30629019)
-
(2000)
Diabetes Research and Clinical Practice
, vol.50
, Issue.1
, pp. 49-56
-
-
Halimi, S.1
Le Berre, M.A.2
Grange, V.3
-
18
-
-
0031765720
-
Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes
-
Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J: Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2050-2055 (Pubitemid 28549150)
-
(1998)
Diabetes Care
, vol.21
, Issue.12
, pp. 2050-2055
-
-
Rosenstock, J.1
Brown, A.2
Fischer, J.3
Jaln, A.4
Littlejohn, T.5
Nadeau, D.6
Sussman, A.7
Taylor, T.8
Krol, A.9
Magner, J.10
-
20
-
-
0012638922
-
Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin
-
DOI 10.2337/diacare.26.2.269
-
Phillips P, Karrasch J, Scott R, Wilson D, Moses R: Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care 2003; 26: 269-273 (Pubitemid 36929042)
-
(2003)
Diabetes Care
, vol.26
, Issue.2
, pp. 269-273
-
-
Phillips, P.1
Karrasch, J.2
Scott, R.3
Wilson, D.4
Moses, R.5
-
21
-
-
33748757957
-
Acarbose/metformin combination versus metformin alone in Indonesian patients with type 2 diabetes
-
Sumual AR, Pandelaki K, Rotty LAW: Acarbose/metformin combination versus metformin alone in Indonesian patients with type 2 diabetes. J Asean Fed Endocrine Soc 2003; 21: 24-31
-
(2003)
J Asean Fed Endocrine Soc
, vol.21
, pp. 24-31
-
-
Sumual, A.R.1
Pandelaki, K.2
Rotty, L.A.W.3
-
22
-
-
0033046464
-
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)
-
DOI 10.2337/diacare.22.6.960
-
Holman RR, Cull CA, Turner RC: A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-964 (Pubitemid 29241052)
-
(1999)
Diabetes Care
, vol.22
, Issue.6
, pp. 960-964
-
-
Holman, R.R.1
Cull, C.A.2
Turner, R.C.3
-
23
-
-
0029658824
-
Mechanisms of the glycaemic effects of sulfonylureas
-
Ashcroft FM: Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996; 28: 456-463
-
(1996)
Horm Metab Res
, vol.28
, pp. 456-463
-
-
Ashcroft, F.M.1
-
24
-
-
0142029443
-
Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas
-
DOI 10.1016/S1056-8727(02)00258-1
-
Lin BJ, Wu HP, Huang HS, Juang JH, Sison A, bin Abdul Kadir DK, Cho CG, Sridama W: Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications 2003; 17: 179-185 (Pubitemid 37297398)
-
(2003)
Journal of Diabetes and Its Complications
, vol.17
, Issue.4
, pp. 179-185
-
-
Lin, B.J.1
Wu, H.-P.2
Huang, H.S.3
Huarng, J.4
Sison, A.5
Bin Abdul Kadir, D.K.6
Cho, C.-G.7
Sridama, W.8
-
25
-
-
0033839370
-
Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes
-
Mughal MA, Memon MY, Zardari MK, Tanwani RK, Ali M: Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes. J Pak Med Assoc 2000; 50: 152-156 (Pubitemid 30663563)
-
(2000)
Journal of the Pakistan Medical Association
, vol.50
, Issue.6
, pp. 152-156
-
-
Mughal, M.A.1
Memon, M.Y.2
Zardari, M.K.3
Tanwani, R.K.4
Ali, M.5
-
26
-
-
0032885589
-
Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study
-
DOI 10.1046/j.1464-5491.1999.00149.x
-
Willms B, Ruge D: Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 755-761 (Pubitemid 29459274)
-
(1999)
Diabetic Medicine
, vol.16
, Issue.9
, pp. 755-761
-
-
Willms, B.1
Ruge, D.2
-
27
-
-
0142105927
-
Long-Term Improvement of Metabolic Control by Acarbose in Type 2 Diabetes Patients Poorly Controlled with Maximum Sulfonylurea Therapy
-
DOI 10.2165/00044011-200323100-00007
-
Bachmann W, Petzinna D, Raptis SA, Wascher T, Westermeier T: Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clin Drug Investig 2003; 23: 679-686 (Pubitemid 37289953)
-
(2003)
Clinical Drug Investigation
, vol.23
, Issue.10
, pp. 679-686
-
-
Bachmann, W.1
Petzinna, D.2
Raptis, S.A.3
Wascher, T.4
Westermeier, T.5
-
28
-
-
0030070954
-
A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients
-
Bayraktar M, Van Thiel DH, Adalar N: A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes Care 1996; 19: 252-254 (Pubitemid 26070353)
-
(1996)
Diabetes Care
, vol.19
, Issue.3
, pp. 252-254
-
-
Bayraktar, M.1
Van Thiel, D.H.2
Adalar, N.3
-
29
-
-
0028357199
-
Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients: The essen study
-
Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994; 17: 561-566 (Pubitemid 24161978)
-
(1994)
Diabetes Care
, vol.17
, Issue.6
, pp. 561-566
-
-
Hoffmann, J.1
Spengler, M.2
-
30
-
-
41749106662
-
Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial
-
Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, Foley JE: Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441
-
(2008)
Diabet Med
, vol.25
, pp. 435-441
-
-
Pan, C.1
Yang, W.2
Barona, J.P.3
Wang, Y.4
Niggli, M.5
Mohideen, P.6
Foley, J.E.7
-
31
-
-
0035904785
-
Insulinotropic meglitinide analogues
-
Dornhorst A: Insulinotropic meglitinide analogues. Lancet 2001; 358: 1709-1716
-
(2001)
Lancet
, vol.358
, pp. 1709-1716
-
-
Dornhorst, A.1
-
33
-
-
4344630260
-
Modification of β-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application
-
Rosak C, Hofmann U, Paulwitz O: Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Diabetes Nutr Metab 2004; 17: 137-142 (Pubitemid 39117273)
-
(2004)
Diabetes, Nutrition and Metabolism - Clinical and Experimental
, vol.17
, Issue.3
, pp. 137-142
-
-
Rosak, C.1
Hofmann, U.2
Paulwitz, O.3
-
34
-
-
67649378996
-
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: A double-blind, cross-over, clinical trial
-
Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF: Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin 2009; 25: 607-615
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 607-615
-
-
Derosa, G.1
Salvadeo, S.A.2
D'Angelo, A.3
Ferrari, I.4
Mereu, R.5
Palumbo, I.6
Maffioli, P.7
Randazzo, S.8
Cicero, A.F.9
-
35
-
-
33646538138
-
Impaired glucose tolerance, diabetes, and cardiovascular disease
-
Schnell O, Standl E: Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006; 12 (Suppl 1): 16-19 (Pubitemid 44963605)
-
(2006)
Endocrine Practice
, vol.12
, Issue.SUPPL. 1
, pp. 16-19
-
-
Schnell, O.1
Standl, E.2
-
36
-
-
0033139266
-
Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients
-
Guvener N, Gedik O: Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. Acta Diabetol 1999; 36: 93-97
-
(1999)
Acta Diabetol
, vol.36
, pp. 93-97
-
-
Guvener, N.1
Gedik, O.2
-
37
-
-
0029032841
-
A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes
-
Coniff RF, Shapiro JA, Seaton TB, Hoogwerf BJ, Hunt JA: A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995; 18: 928-932
-
(1995)
Diabetes Care
, vol.18
, pp. 928-932
-
-
Coniff, R.F.1
Shapiro, J.A.2
Seaton, T.B.3
Hoogwerf, B.J.4
Hunt, J.A.5
-
38
-
-
0031767296
-
Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes
-
Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J: Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998; 21: 2056-2061 (Pubitemid 28549151)
-
(1998)
Diabetes Care
, vol.21
, Issue.12
, pp. 2056-2061
-
-
Kelley, D.E.1
Bidot, P.2
Freedman, Z.3
Haag, B.4
Podlecki, D.5
Rendell, M.6
Schimel, D.7
Weiss, S.8
Taylor, T.9
Krol, A.10
Magner, J.11
-
39
-
-
0033855806
-
Effect of acarbose on insulin sensitivity in elderly patients with diabetes
-
Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D: Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23: 1162-1167 (Pubitemid 30616806)
-
(2000)
Diabetes Care
, vol.23
, Issue.8
, pp. 1162-1167
-
-
Meneilly, G.S.1
Ryan, E.A.2
Radziuk, J.3
Lau, D.C.W.4
Yale, J.-F.5
Morais, J.6
Chiasson, J.-L.7
Rabasa-Lhoret, R.8
Maheux, P.9
Tessier, D.10
Wolever, T.11
Josse, R.G.12
Elahi, D.13
-
40
-
-
0035986333
-
Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients
-
Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A: Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200 (Pubitemid 34746953)
-
(2002)
Diabetes and Metabolism
, vol.28
, Issue.3
, pp. 195-200
-
-
Delgado, H.1
Lehmann, T.2
Bobbioni-Harsch, E.3
Ybarra, J.4
Golay, A.5
-
41
-
-
0035030824
-
Safety and efficacy of acarbose in the treatment of type 2 diabetes: Data from a 5-year surveillance study
-
Mertes G: Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001; 52: 193-204
-
(2001)
Diabetes Res Clin Pract
, vol.52
, pp. 193-204
-
-
Mertes, G.1
-
42
-
-
0030870853
-
Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes
-
Wolever TMS, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH: Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Nature 1997; 21: 756-763
-
(1997)
Nature
, vol.21
, pp. 756-763
-
-
Wolever, T.M.S.1
Chiasson, J.L.2
Josse, R.G.3
Hunt, J.A.4
Palmason, C.5
Rodger, N.W.6
Ross, S.A.7
Ryan, E.A.8
Tan, M.H.9
-
43
-
-
25644461255
-
Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus
-
DOI 10.2165/00044011-200525090-00003
-
Neuser D, Benson A, Bruckner A, Goldberg RB, Hoogwerf BJ, Petzinna D: Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig 2005; 25: 579-587 (Pubitemid 41379848)
-
(2005)
Clinical Drug Investigation
, vol.25
, Issue.9
, pp. 579-587
-
-
Neuser, D.1
Benson, A.2
Bruckner, A.3
Goldberg, R.B.4
Hoogwerf, B.J.5
Petzinna, D.6
-
44
-
-
25644435031
-
Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus
-
DOI 10.2165/00044011-200525090-00004
-
Segal P, Eliahou HE, Petzinna D, Neuser D, Bruckner A, Spengler M: Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clin Drug Investig 2005; 25: 589-595 (Pubitemid 41379849)
-
(2005)
Clinical Drug Investigation
, vol.25
, Issue.9
, pp. 589-595
-
-
Segal, P.1
Eliahou, H.E.2
Petzinna, D.3
Neuser, D.4
Bruckner, A.5
Spengler, M.6
-
45
-
-
0031777678
-
The PROTECT Study: Final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies
-
Buse J, Hart K, Minasi L: The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther 1998; 20: 257-269
-
(1998)
Clin Ther
, vol.20
, pp. 257-269
-
-
Buse, J.1
Hart, K.2
Minasi, L.3
-
46
-
-
0029941276
-
An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM
-
Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, Hotta N: An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM. Diabetes Care 1996; 19: 642-647 (Pubitemid 26181114)
-
(1996)
Diabetes Care
, vol.19
, Issue.6
, pp. 642-647
-
-
Hara, T.1
Nakamura, J.2
Koh, N.3
Sakakibara, F.4
Takeuchi, N.5
Hotta, N.6
-
47
-
-
0036211095
-
Acarbose, an update of its therapeutic use in diabetes treatment
-
Laube H: Acarbose, an update of its therapeutic use in diabetes treatment. Clin Drug Investig 2002; 22: 141-156
-
(2002)
Clin Drug Investig
, vol.22
, pp. 141-156
-
-
Laube, H.1
-
48
-
-
0021854758
-
Adaptation of the small intestine to induced maldigestion in rats. Experimental pancreatic atrophy and acarbose feeding
-
Creutzfeldt W, Folsch UR, Elsenhans B, Ballmann M, Conlon JM: Adaptation of the small intestine to induced maldigestion in rats. Experimental pancreatic atrophy and acarbose feeding. Scand J Gastroenterol 1985; 112 (Suppl): 45-53 (Pubitemid 15029602)
-
(1985)
Scandinavian Journal of Gastroenterology, Supplement
, vol.20
, Issue.SUPPL. 112
, pp. 45-53
-
-
Creutzfeldt, W.1
Folsch, U.R.2
Elsenhans, B.3
-
49
-
-
0000535567
-
Influence of long-term intake of a glykosidehydrolaseinhibitor (BAY g 5421) on pancreatic exocrine secretion and contents of intestinal brush-border-enzymes
-
Folsch UR, van Schwamen E, Graf S, Caspary WF, Creutzfeldt W: Influence of long-term intake of a glykosidehydrolaseinhibitor (BAY g 5421) on pancreatic exocrine secretion and contents of intestinal brush-border-enzymes. Gastroent Clin Biol 1979; 3: 286-287
-
(1979)
Gastroent Clin Biol
, vol.3
, pp. 286-287
-
-
Folsch, U.R.1
Van Schwamen, E.2
Graf, S.3
Caspary, W.F.4
Creutzfeldt, W.5
-
50
-
-
0024343686
-
Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of (14C) acarbose to rats, dogs and man
-
Ahr HJ, Boberg M, Krause HP, Maul W, Muller FO, Ploschke HJ, Weber H, Wunsche C: Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of (14C) acarbose to rats, dogs and man. Arzneimittelforschung 1989; 39: 1254-1260
-
(1989)
Arzneimittelforschung
, vol.39
, pp. 1254-1260
-
-
Ahr, H.J.1
Boberg, M.2
Krause, H.P.3
Maul, W.4
Muller, F.O.5
Ploschke, H.J.6
Weber, H.7
Wunsche, C.8
-
51
-
-
0024317398
-
Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of (14C)acarbose to rats and dogs
-
Ahr HJ, Krause HP, Siefert HM, Steinke W, Weber H: Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of (14C)acarbose to rats and dogs. Arzneimittelforschung 1989; 39: 1261-1267
-
(1989)
Arzneimittelforschung
, vol.39
, pp. 1261-1267
-
-
Ahr, H.J.1
Krause, H.P.2
Siefert, H.M.3
Steinke, W.4
Weber, H.5
-
52
-
-
57149101128
-
The role of acarbose in type 2 diabetes combination therapy
-
Rosak C: The role of acarbose in type 2 diabetes combination therapy. Diabetes Stoffw Herz 2007; 16: 119-126
-
(2007)
Diabetes Stoffw Herz
, vol.16
, pp. 119-126
-
-
Rosak, C.1
-
53
-
-
0034872965
-
Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis
-
DOI 10.1046/j.1463-1326.2001.00103.x
-
Gentile S, Turco S, Guarino G, Oliviero B, Annunziata S, Cozzolino D, Sasso FC, Turco A, Salvatore T, Torella R: Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab 2001; 3: 33-40 (Pubitemid 32782851)
-
(2001)
Diabetes, Obesity and Metabolism
, vol.3
, Issue.1
, pp. 33-40
-
-
Gentile, S.1
Turco, S.2
Guarino, G.3
Oliviero, B.4
Annunziata, S.5
Cozzolino, D.6
Sasso, F.C.7
Turco, A.8
Salvatore, T.9
Torella, R.10
-
54
-
-
24944497145
-
Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus a postmarketing surveillance study
-
DOI 10.2165/00044011-200525100-00004
-
Spengler M, Schmitz H, Landen H: Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus : a postmarketing surveillance study. Clin Drug Investig 2005; 25: 651-659 (Pubitemid 41330307)
-
(2005)
Clinical Drug Investigation
, vol.25
, Issue.10
, pp. 651-659
-
-
Spengler, M.1
Schmitz, H.2
Landen, H.3
-
55
-
-
33748784333
-
Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus
-
DOI 10.2165/00044011-200626100-00002
-
Hung YJ, Kuo SW, Wang CH, Chang HY, Hsieh SH, Landen H: Postmarketing surveillance of acarbose treatment in Taiwanese patients with type 2 diabetes mellitus. Clin Drug Investig 2006; 26: 559-565 (Pubitemid 44411331)
-
(2006)
Clinical Drug Investigation
, vol.26
, Issue.10
, pp. 559-565
-
-
Hung, Y.-J.1
Kuo, S.-W.2
Wang, C.-H.3
Chang, H.-Y.4
Hsieh, S.-H.5
Landen, H.6
-
56
-
-
34249898882
-
Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China
-
DOI 10.2165/00044011-200727060-00003
-
Pan CY, Landen H: Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Investig 2007; 27: 397-405 (Pubitemid 46873101)
-
(2007)
Clinical Drug Investigation
, vol.27
, Issue.6
, pp. 397-405
-
-
Pan, C.-Y.1
Landen, H.2
-
57
-
-
42249106872
-
Efficacy, safety and acceptance of acarbose treatment under day-to-day practice conditions: A post-marketing surveillance of Chinese type 2 diabetic patients
-
Su SO, Zhao JJ, Zhang J, D.J. Z, Li H, Sheng ZY, Liang GX, Landen H: Efficacy, safety and acceptance of acarbose treatment under day-to-day practice conditions: a post-marketing surveillance of Chinese type 2 diabetic patients. Chin J Endocrinol Metab 2006; 22: a-1-a-5
-
(2006)
Chin J Endocrinol Metab
, vol.22
-
-
Su, S.O.1
Zhao, J.J.2
Zhang, J.D.J.Z.3
Li, H.4
Sheng, Z.Y.5
Liang, G.X.6
Landen, H.7
-
58
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
-
(2009)
N Engl J Med
, vol.360
, pp. 129-139
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
Reda, D.4
Emanuele, N.5
Reaven, P.D.6
Zieve, F.J.7
Marks, J.8
Davis, S.N.9
Hayward, R.10
Warren, S.R.11
Goldman, S.12
McCarren, M.13
Vitek, M.E.14
Henderson, W.G.15
Huang, G.D.16
-
59
-
-
45149131667
-
Effects of intensive glucose lowering in type 2 diabetes
-
Action to Control Cardiovascular Risk in Diabetes Study Group
-
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559
-
(2008)
N Engl J Med
, vol.358
, pp. 2545-2559
-
-
Gerstein, H.C.1
Miller, M.E.2
Byington, R.P.3
Goff Jr., D.C.4
Bigger, J.T.5
Buse, J.B.6
Cushman, W.C.7
Genuth, S.8
Ismail-Beigi, F.9
Grimm Jr., R.H.10
Probstfield, J.L.11
Simons-Morton, D.G.12
Friedewald, W.T.13
-
60
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
ADVANCE Collaborative Group
-
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
-
(2008)
N Engl J Med
, vol.358
, pp. 2560-2572
-
-
Patel, A.1
MacMahon, S.2
Chalmers, J.3
Neal, B.4
Billot, L.5
Woodward, M.6
Marre, M.7
Cooper, M.8
Glasziou, P.9
Grobbee, D.10
Hamet, P.11
Harrap, S.12
Heller, S.13
Liu, L.14
Mancia, G.15
Mogensen, C.E.16
Pan, C.17
Poulter, N.18
Rodgers, A.19
Williams, B.20
Bompoint, S.21
De Galan, B.E.22
Joshi, R.23
Travert, F.24
more..
|